Prescription for growth

We, at biotuesdays.com, attended Dundee Capital Markets’ second emerging growth conference last week, where over 20 technology, life sciences and industrial growth companies presented. Dundee specializes in early-stage growth, and to say that the one-day showcase was jammed full of investment ideas is a bit of understatement. Here’s a sampling of what we took away [...]

Bioniche to offer 20 million shares

Bioniche Life Sciences (TSX:BNC) is offering up to 20 million new common shares in two concurrent financings by short-form prospectus in all provinces of Canada and by initial public offering in Australia and New Zealand. Stock may be offered in other jurisdictions on a private placement basis. The Canadian sale is being underwritten by a [...]

Bioniche links future disclosure to trading activity

Bioniche Life Sciences (TSX:BNC) expects to make a statement within the next several weeks about its Phase 3 clinical trial with its bladder cancer drug Urocidin. The company made the disclosure in response to recent activity in shares, noting that it believes the jump in volume and share price was driven by expectations of a statement [...]

Bioniche-Endo set for additional Phase 3 trial

Bioniche Life Sciences (TSX:BNC) and its development partner, Endo Pharmaceuticals (NASDAQ: ENDP), are in the process of finalizing a protocol for an additional Phase 3 clinical trial of their Urocidin bladder cancer drug, which is expected to begin enrolling patients in 2010. “We’re preparing to initiate a large study with Urocidin in the second half [...]

Riding the Next Wave

No, we’re not talking about the north coast of Maui but rather a new research platform from long-time biotech analyst David Martin of Dundee Securities. “If I’m going to recommend that investors own a basket of biotech stocks, it makes sense that I ought to initiate on a basket of stocks rather than make one-off [...]